Pediatric psoriasis: Should we be concerned with comorbidity? Cross‐sectional study

Kelati, Awatef; Baybay, Hanane; Najdi, Adil; Zinoune, S.; Mernissi, F.Z.

doi:10.1111/ped.13309

Cited by 18 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36 The strength of recommendations and levels of evidence for psoriasis and obesity are summarized in Tables VI and VII. 11,12,25,27,[30][31][32][33][34][35]37,38…”

Section: Psoriatic Arthritismentioning

confidence: 99%

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Menter

Cordoro

Davis

et al. 2020

Journal of the American Academy of Dermatology

150

176

View full text Add to dashboard Cite

“…36 The strength of recommendations and levels of evidence for psoriasis and obesity are summarized in Tables VI and VII. 11,12,25,27,[30][31][32][33][34][35]37,38…”

Section: Psoriatic Arthritismentioning

confidence: 99%

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Menter

Cordoro

Davis

et al. 2020

Journal of the American Academy of Dermatology

150

176

View full text Add to dashboard Cite

“…Recently, a mutation in the interleukin 36 receptor antagonist gene leading to a defect in interleukin 36 antagonist was identified in generalized pustular psoriasis and acrodermatitis continua suppurativa supporting the view that it belongs to the autoinflammatory diseases group. 5 , 6 Pustulosis palmoplantaris is histopathologically and genetically different and rarely affects the periungual skin. 7 …”

Section: Clinical Characteristics Of Nail Psoriasismentioning

confidence: 99%

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management

Haneke¹

2017

PTT

View full text Add to dashboard Cite

Psoriasis is the skin disease that most frequently affects the nails. Depending on the very nail structure involved, different clinical nail alterations can be observed. Irritation of the apical matrix results in psoriatic pits, mid-matrix involvement may cause leukonychia, whole matrix affection may lead to red lunulae or severe nail dystrophy, nail bed involvement may cause salmon spots, subungual hyperkeratosis, and splinter hemorrhages, and psoriasis of the distal nail bed and hyponychium causes onycholysis whereas that of the proximal nail fold causes psoriatic paronychia. The more extensive the involvement, the more severe is the nail destruction. Pustular psoriasis may be seen as yellow spots under the nail or, in case of acrodermatitis continua suppurativa, as an insidious progressive loss of the nail organ. Nail psoriasis has a severe impact on quality of life and may interfere with professional and other activities. Management includes patient counseling, avoidance of stress and strain to the nail apparatus, and different types of treatment. Topical therapy may be tried but is rarely sufficiently efficient. Perilesional injections with corticosteroids and methotrexate are often beneficial but may be painful and cannot be applied to many nails. All systemic treatments clearing widespread skin lesions usually also clear the nail lesions. Recently, biologicals were introduced into nail psoriasis treatment and found to be very effective. However, their use is restricted to severe cases due to high cost and potential systemic adverse effects.

show abstract

“…Carobbo et al [ 16 ] found hypertension, in the single-center study, in eight out of 60 patients (13% of the entire cohort). In contrast, in a cross-sectional study by Kelati et al [ 19 ] involving 84 children with psoriasis and comorbidities, no cases of arterial hypertension were detected. In the meta-analysis performed by Pietrzak et al [ 15 ], similarly, there was no difference in the systolic and diastolic blood pressure between the group of psoriatic children and the control group.…”

Section: Cardiovascular Diseasesmentioning

confidence: 75%

Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review

et al. 2022

View full text Add to dashboard Cite

Psoriasis vulgaris is a common inflammatory, immune mediated, chronic recurrent dermatosis. Psoriasis is also a systemic inflammatory disease, associated with numerous comorbidities, particularly metabolic ones. Here, we summarize and discuss, in a narrative review, the current knowledge about the metabolic comorbidities in psoriatic children. Obesity, insulin resistance, diabetes, cardiovascular disease, and dyslipidemia are identified as the main comorbidities in psoriatic children. In conclusion, dermatologists should be aware of the metabolic comorbidities in children with psoriasis, modulating the therapeutic approach according to the patient’s clinical condition.

show abstract

Pediatric psoriasis: Should we be concerned with comorbidity? Cross‐sectional study

Cited by 18 publications

References 24 publications

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management

Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review

Contact Info

Product

Resources

About